Danske Bank A S Increases Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• Danske Bank increased its stake in Charles River by 96.1% in Q4, buying an additional 25,005 shares to own 51,016 shares (about 0.10% of the company) valued at roughly $10.18 million.
• Institutional ownership is highly concentrated at 98.91%, with several other funds making modest position changes during recent quarters.
• The stock carries a consensus "Moderate Buy" rating with a $205.36 target; notable analyst actions include Citigroup lifting its target to $265, and company FY2026 EPS guidance set at 10.700–11.200 after a modest quarterly beat (EPS $2.39 vs. $2.33 estimate).

Danske Bank A S lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 96.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,016 shares of the medical research company's stock after buying an additional 25,005 shares during the quarter. Danske Bank A S owned approximately 0.10% of Charles River Laboratories International worth $10,177,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in CRL. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $26,000. Rothschild Investment LLC grew its position in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock worth $29,000 after buying an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International during the third quarter worth $31,000. Activest Wealth Management grew its stake in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company's stock worth $44,000 after purchasing an additional 218 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock worth $44,000 after purchasing an additional 145 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Citigroup boosted their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a "buy" rating in a research note on Friday, January 16th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an "outperform" rating and a $215.00 target price for the company. Barclays boosted their target price on shares of Charles River Laboratories International from $200.00 to $210.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 14th. Evercore reaffirmed an "outperform" rating on shares of Charles River Laboratories International in a report on Wednesday, April 8th. Finally, Wall Street Zen downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, February 21st. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $205.36.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $172.10 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International, Inc. has a 1 year low of $113.89 and a 1 year high of $228.88. The company has a market capitalization of $8.49 billion, a PE ratio of -58.14, a P/E/G ratio of 2.01 and a beta of 1.44. The company has a fifty day moving average of $169.78 and a two-hundred day moving average of $183.17.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the prior year, the firm posted $2.66 earnings per share. Charles River Laboratories International's revenue for the quarter was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 10.97 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.